Literature DB >> 27608893

Correlation of multiple proteins with clinic-pathological features and its prognostic significance in colorectal cancer with signet-ring cell component.

X Cai1, W-X Qi, L Wang, Z Zhang.   

Abstract

OBJECTIVE: Primary colorectal cancer (CRC) with signet-ring cell (SRC) component is a distinct tumor of colon and rectum, and its prognosis is very poor. Reliable markers to predict the poor clinical outcome of this subgroup cancer remains undetermined. Therefore, we perform this study to investigate the prognosis value of seven proteins in CRC with SRC component . PATIENTS AND METHODS: This study involved 117 patients diagnosed with CRC with SRC component between January 2008 and August 2015 at Fudan University Shanghai Cancer Center. The samples from these patients were analyzed by immunohistochemistry to reveal the expression levels of p53, p21, E-cadherin, COX-2 (Cyclo-oxygenase-2), Bcl-2, CD44 and Ki-67. Kaplan-Meier analysis and log-rank testing were performed to estimate survival. Subsequently, a Cox proportional hazard model was used to calculate hazard ratios for the risk of death.
RESULTS: The p21, p53, COX-2, E-cadherin, Bcl-2, CD44 and Ki-67 expression were detected in 60.5%, 61.3%, 69.7%, 68%, 28.6%, 62.2% and 75.6% of the samples, respectively. The positive expression of p53 (p=0.017) and the negative expression of COX-2 (p=0.001) or E-cadherin (p=0.047) in CRC with SRC component were significantly associated with decreased overall survival, but the other expression levels were not. In a multivariate analysis, the negative expression of COX-2 was found to be an independent prognostic factor for poorer overall survival (hazard ratio, 0.37; 95% confidence interval, 0.19 to 0.75, p=0.003)
CONCLUSIONS: The COX-2 positive expression in CRC patients with SRC component had a poorer outcome than patients who were COX-2-negative. Therefore, COX-2 could be considered as an indicator for appropriate treatment and intensive follow-up in these subgroup patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27608893

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

Review 1.  Effect of E-cadherin on Prognosis of Colorectal Cancer: A Meta-Analysis Update.

Authors:  Kaibin Chang; Lei Jiang; Yifeng Sun; He Li
Journal:  Mol Diagn Ther       Date:  2022-06-22       Impact factor: 4.476

2.  Colorectal Cancer Prognosis: The Impact of Signet Ring Cell.

Authors:  Refik Bademci; Jesus Bollo; M Carmen Martinez; Maria Pilar Hernadez; Eduardo Maria Targarona
Journal:  Gastrointest Tumors       Date:  2019-07-31

Review 3.  High expression of anti-apoptotic protein Bcl-2 is a good prognostic factor in colorectal cancer: Result of a meta-analysis.

Authors:  Qi Huang; Shu Li; Pu Cheng; Mei Deng; Xin He; Zhen Wang; Cheng-Hui Yang; Xiao-Ying Zhao; Jian Huang
Journal:  World J Gastroenterol       Date:  2017-07-21       Impact factor: 5.742

4.  E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors.

Authors:  Eike Burandt; Felix Lübbersmeyer; Natalia Gorbokon; Franziska Büscheck; Andreas M Luebke; Anne Menz; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Sören Weidemann; Christoph Fraune; Katharina Möller; Frank Jacobsen; Patrick Lebok; Till Sebastian Clauditz; Guido Sauter; Ronald Simon; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Sarah Minner; Rainer Krech; David Dum; Till Krech; Andreas Holger Marx; Christian Bernreuther
Journal:  Biomark Res       Date:  2021-06-05

5.  PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+γδ Treg polarization.

Authors:  Yang Zhan; Lei Zheng; Jia Liu; Dongzhi Hu; Junfeng Wang; Kai Liu; Jiansheng Guo; Ti Zhang; Dalu Kong
Journal:  JCI Insight       Date:  2021-08-23

6.  The prognostic significance of different proportion of signet-ring cells of colorectal carcinoma.

Authors:  Wei Chen; Huajun Cai; Kui Chen; Xing Liu; Weizhong Jiang; Shoufeng Li; Yiyi Zhang; Zhifen Chen; Guoxian Guan
Journal:  Bosn J Basic Med Sci       Date:  2022-02-01       Impact factor: 3.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.